Literature DB >> 33786251

Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.

Srikrishna V Malayala1, Gisha Mohan2, Deepa Vasireddy3, Paavani Atluri4.   

Abstract

The mRNA-1273 vaccine, popularly called the "Moderna vaccine" is being widely administered in the United States for the prevention of COVID-19 infection since December 2020. Mild to moderate intensity side effects like low-grade fever, myalgia, chills and malaise were reported in the trials related to the vaccine. With this case report, we report a case of purpuric rash and thrombocytopenia after receiving the first dose of the m-RNA-1273 vaccine. The patient, in this case, is a 60-year-old male patient who received the first vaccine dose and within two days, he developed diffuse papular rash associated with some thrombocytopenia. He had a history of tobacco use, Hepatitis C liver cirrhosis, chronic kidney disease stage 4, untreated hypertension and systolic congestive heart failure at the baseline. With review of the limited literature related to the vaccine and its side effect profile and with no other etiology explaining the sudden onset of rash, we attribute this thrombocytopenia and purpuric rash as the side effects of the mRNA-1273 vaccine.
Copyright © 2021, Malayala et al.

Entities:  

Keywords:  covid 19; drug rash; drug-induced itp; immune thrombocytopenia purpura; mrna-based vaccine

Year:  2021        PMID: 33786251      PMCID: PMC7996471          DOI: 10.7759/cureus.14099

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  16 in total

1.  MMR vaccine and idiopathic thrombocytopaenic purpura.

Authors:  Corri Black; James A Kaye; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 2.  Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins.

Authors:  J N George
Journal:  Blood       Date:  1990-09-01       Impact factor: 22.113

Review 3.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

4.  Management of immune thrombocytopenic purpura: an update.

Authors:  Rajasekharan Warrier; Aman Chauhan
Journal:  Ochsner J       Date:  2012

Review 5.  Infections and autoimmunity--friends or foes?

Authors:  Shaye Kivity; Nancy Agmon-Levin; Miri Blank; Yehuda Shoenfeld
Journal:  Trends Immunol       Date:  2009-07-28       Impact factor: 16.687

6.  Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.

Authors:  Eric K France; Jason Glanz; Stanley Xu; Simon Hambidge; Kristi Yamasaki; Steve B Black; Michael Marcy; John P Mullooly; Lisa A Jackson; James Nordin; Edward A Belongia; K Hohman; Robert T Chen; Robert Davis
Journal:  Pediatrics       Date:  2008-03       Impact factor: 7.124

7.  An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Authors:  Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel
Journal:  N Engl J Med       Date:  2020-07-14       Impact factor: 91.245

Review 8.  Vaccines, adjuvants and autoimmunity.

Authors:  Luísa Eça Guimarães; Britain Baker; Carlo Perricone; Yehuda Shoenfeld
Journal:  Pharmacol Res       Date:  2015-08-12       Impact factor: 7.658

9.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

10.  Postinfluenza Vaccination Idiopathic Thrombocytopenic Purpura in Three Elderly Patients.

Authors:  Joji Nagasaki; Masahiro Manabe; Kentaro Ido; Hiroyoshi Ichihara; Yasutaka Aoyama; Tadanobu Ohta; Yoshio Furukawa; Atsuko Mugitani
Journal:  Case Rep Hematol       Date:  2016-02-21
View more
  23 in total

1.  COVID-19 infection after mRNA 1273 vaccine: review of the most frequently asked questions.

Authors:  Rachana Vanaparthy; Srikrishna Varun Malayala; Hira Rehman; Shwetha Guttha; Gisha Mohan; Deepa Vasireddy; Paavani Atluri
Journal:  Infez Med       Date:  2021-09-10

Review 2.  COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.

Authors:  Naim Mahroum; Noy Lavine; Aviran Ohayon; Ravend Seida; Abdulkarim Alwani; Mahmoud Alrais; Magdi Zoubi; Nicola Luigi Bragazzi
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

3.  A Case of COVID-19 Induced Descending Aortic Thrombus and Splenic Infarctions.

Authors:  Srikrishna V Malayala; Syed Bukhari; Rachana Vanaparthy; Ambreen Raza; Ramya Akella
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-09-09

4.  Not only toes and fingers: COVID vaccine-induced chilblain-like lesions of the knees.

Authors:  A Bassi; C Mazzatenta; A Sechi; M Cutrone; V Piccolo
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-08       Impact factor: 9.228

5.  Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection.

Authors:  Po-Wei Liao; Chieh-Lin Jerry Teng; Cheng-Wei Chou
Journal:  Vaccines (Basel)       Date:  2021-12-16

Review 6.  Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective.

Authors:  Dennis Niebel; Natalija Novak; Jasmin Wilhelmi; Jana Ziob; Dagmar Wilsmann-Theis; Thomas Bieber; Joerg Wenzel; Christine Braegelmann
Journal:  Vaccines (Basel)       Date:  2021-08-25

Review 7.  A comprehensive review on efficient approaches for combating coronaviruses.

Authors:  Mahdi Pouresmaieli; Elena Ekrami; Ali Akbari; Negin Noorbakhsh; Negin Borzooee Moghadam; Matin Mamoudifard
Journal:  Biomed Pharmacother       Date:  2021-10-22       Impact factor: 6.529

8.  COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis.

Authors:  Clio Bilotta; Giulio Perrone; Valeria Adelfio; Giovanni Francesco Spatola; Maria Laura Uzzo; Antonina Argo; Stefania Zerbo
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

9.  Immune thrombocytopenic purpura associated with COVID-19 Pfizer-BioNTech BNT16B2b2 mRNA vaccine.

Authors:  P K Krajewski; J C Szepietowski
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-16       Impact factor: 9.228

10.  Immune Thrombocytopenic Purpura Cases Following COVID-19 Vaccination.

Authors:  Annalisa Condorelli; Uros Markovic; Roberta Sciortino; Mary Ann Di Giorgio; Daniela Nicolosi; Gaetano Giuffrida
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-03-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.